JPE-1375

CAT: 0804-HY-148141-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-148141-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 μM) and reduces TNF levels (EC50=4.5 μM) in mice. JPE-1375 can be used in studies of autoimmune and inflammatory diseases[1].
CAS Number
[1254036-23-1]
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Complement System
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/jpe-1375.html
Purity
99.96
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C([C@@H]1CC(NC(N1)=O)=O)N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCCN)C(N3[C@@H](CCC3)C(N[C@@H](CCC(C)C)C(N[C@H](C(N[C@H](C(N)=O)CC4=CC=CC=C4)=O)CC5=CC=C(C=C5)F)=O)=O)=O)=O
Molecular Formula
C49H63FN10O9
Molecular Weight
955.08
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Cui CS, et al. In Vivo Pharmacodynamic Method to Assess Complement C5a Receptor Antagonist Efficacy. ACS Pharmacol Transl Sci. 2021 Dec 21;5 (1) :41-51.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products